Literature DB >> 23420591

Therapeutic plasma exchange in neurology: 2012.

Irene Cortese1, David R Cornblath.   

Abstract

In treating neuroimmunological diseases, neurologists have a number of different drugs to choose from ranging from corticosteroids to IVIg to more specific cell based therapies, the latter most frequently from the world of oncology. In some diseases, therapeutic plasma exchange, a procedure rather than a drug, is used. The most obvious advantage of therapeutic plasma exchange is the usually rapid onset of action presumably due to removal of pathogenic auto-antibodies. In some diseases, a single course of therapeutic plasma exchange is used while in others prolonged treatment with therapeutic plasma exchange is used. This article will review the use of therapeutic plasma exchange in neurology and will draw heavily upon recent consensus statements from the American Society for Apheresis and the American Academy of Neurology and by Cochrane reviews.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23420591      PMCID: PMC3615701          DOI: 10.1002/jca.21266

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  23 in total

Review 1.  Guillain-Barré syndrome.

Authors:  Nobuhiro Yuki; Hans-Peter Hartung
Journal:  N Engl J Med       Date:  2012-06-14       Impact factor: 91.245

Review 2.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  Michael P T Lunn; Eduardo Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.

Authors:  P C Dau; J M Lindstrom; C K Cassel; E H Denys; E E Shev; L E Spitler
Journal:  N Engl J Med       Date:  1977-11-24       Impact factor: 91.245

4.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

Review 5.  Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  M M Mehndiratta; R A Hughes
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 6.  Intravenous immunoglobulin for Guillain-Barré syndrome.

Authors:  Richard A C Hughes; Anthony V Swan; Pieter A van Doorn
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 7.  Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  M M Mehndiratta; R A C Hughes; P Agarwal
Journal:  Cochrane Database Syst Rev       Date:  2004

8.  Assessment of plasmapheresis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors: 
Journal:  Neurology       Date:  1996-09       Impact factor: 9.910

Review 9.  Plasma exchange for myasthenia gravis.

Authors:  P Gajdos; S Chevret; K Toyka
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 10.  Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.

Authors:  Nobuhiro Yuki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

View more
  12 in total

Review 1.  Inflammation in CNS neurodegenerative diseases.

Authors:  Jodie Stephenson; Erik Nutma; Paul van der Valk; Sandra Amor
Journal:  Immunology       Date:  2018-04-17       Impact factor: 7.397

2.  Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.

Authors:  Mercè Boada; Fernando Anaya; Pilar Ortiz; Javier Olazarán; Joshua R Shua-Haim; Thomas O Obisesan; Isabel Hernández; Joan Muñoz; Mar Buendia; Montserrat Alegret; Asunción Lafuente; Lluís Tárraga; Laura Núñez; Mireia Torres; Joan Ramon Grifols; Isidre Ferrer; Oscar L Lopez; Antonio Páez
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Effect of plasmapheresis on serum levels of clobazam, levetiracetam and topiramate.

Authors:  To Harmony Hau Man; Chang Richard Shek-Kwan; Chan Angel On-Kei; Chan Phoebe Wing Lam
Journal:  Epilepsy Behav Case Rep       Date:  2017-07-19

4.  Therapeutic apheresis within immune-mediated neurological disorders: dosing and its effectiveness.

Authors:  Matthias Klingele; Carina Allmendinger; Solmaz Thieme; Lea Baerens; Danilo Fliser; Bürmann Jan
Journal:  Sci Rep       Date:  2020-05-13       Impact factor: 4.379

5.  Therapeutic Plasma Exchange in Multiple Sclerosis and Autoimmune Encephalitis: a Comparative Study of Indication, Efficacy and Safety.

Authors:  Tobias Moser; Gayane Harutyunyan; Anush Karamyan; Ferdinand Otto; Carola Bacher; Vaclav Chroust; Markus Leitinger; Helmut F Novak; Eugen Trinka; Johann Sellner
Journal:  Brain Sci       Date:  2019-10-09

Review 6.  Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.

Authors:  Paolo Ripellino; Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Autoimmune Dis       Date:  2014-01-14

7.  Altered cerebral glucose metabolism normalized in a patient with a pediatric autoimmune neuropsychiatric disorder after streptococcal infection (PANDAS)-like condition following treatment with plasmapheresis: a case report.

Authors:  A H Nave; P Harmel; R Buchert; L Harms
Journal:  BMC Neurol       Date:  2018-05-02       Impact factor: 2.474

8.  Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders.

Authors:  Michael Levy
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-09-26

9.  AMBAR, an Encouraging Alzheimer's Trial That Raises Questions.

Authors:  David A Loeffler
Journal:  Front Neurol       Date:  2020-05-29       Impact factor: 4.003

Review 10.  Paraneoplastic Diseases of the Central Nervous System.

Authors:  Jonathan Galli; John Greenlee
Journal:  F1000Res       Date:  2020-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.